<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> occurring after multi-drug chemotherapy are rare; they are more often associated with the use of <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We report the case history of a patient with myelodyspasia occurring after neoadjuvant <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> and <z:chebi fb="0" ids="27504">mitomycin C</z:chebi> (triple M) chemotherapy with subsequent radiotherapy for locally advanced <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Cytogenetic analysis of a bone marrow biopsy confirmed the typical chromosomal abnormalities associated with therapy related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Few treatments for this disorder have been found to be of value </plain></SENT>
<SENT sid="4" pm="."><plain>The aetiology, incidence and management options are briefly discussed </plain></SENT>
</text></document>